聚乙二醇化腺苷脱氨酶在系统性硬化症临床前模型中改善炎症、血管病变与纤维化
本研究在Fra-2小鼠和硬皮病慢性GVHD小鼠模型中评估PEG-ADA的治疗效果,并在人全层皮肤模型中体外验证。PEG-ADA抑制肌成纤维细胞分化,减轻肺、皮肤和肠道纤维化,改善炎症和血管病变,且所用剂量具有药理学相关性且耐受良好。
要点
- PEG-ADA在两种SSc临床前模型中减轻纤维化、炎症和血管病变。
- PEG-ADA已获FDA批准用于ADA缺陷型重症联合免疫缺陷病,具有转化潜力。
- 体外人全层皮肤模型验证了PEG-ADA的抗纤维化作用。
核心结论
- PEG-ADA在药理学相关且耐受良好的剂量下改善SSc的三大核心特征:纤维化、血管病变和炎症。
研究设计与样本
- 在Fra-2小鼠和B10.D2→BALB/c(H-2d)硬皮病慢性GVHD模型中分析PEG-ADA对炎症、血管重塑和组织纤维化的影响。
- 在体外人全层皮肤模型中确认PEG-ADA的效果。
主要发现
- 在Fra-2小鼠中,PEG-ADA使肺纤维化减少34.3%(P=0.0079;n=6),皮肤纤维化减少51.8%(P=0.0006;n=6),肠道纤维化减少17.7%(P=0.0228;n=6)。
- 在硬皮病慢性GVHD模型中,PEG-ADA使纤维化减少38.4%(P=0.0063;n=8)。
- PEG-ADA减少炎症并纠正M2/Th2/2型固有淋巴细胞2偏倚。
- PEG-ADA使肺血管平滑肌细胞增殖减少40.5%(P<0.0001;n=6),血管壁增厚减少39.6%(P=0.0028;n=6),肺动脉闭塞减少63.9%(P=0.0147;n=6)。
- PEG-ADA使微血管内皮细胞凋亡减少65.4%(P=0.0001;n=6),毛细血管稀疏减少32.5%(P=0.0199;n=6)。
临床怎么用
- PEG-ADA已获FDA批准用于ADA缺陷型重症联合免疫缺陷病,可能具有直接的转化意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is characterized by fibrosis, vascular disease, and inflammation. Adenosine signaling plays a central role in fibroblast activation. We undertook this study to evaluate the therapeutic effects of adenosine depletion with PEGylated adenosine deaminase (PEG-ADA) in preclinical models of SSc. METHODS: The effects of PEG-ADA on inflammation, vascular remodeling, and tissue fibrosis were analyzed in Fra-2 mice and in a B10.D2→BALB/c (H-2d ) model of sclerodermatous chronic graft-versus-host disease (GVHD). The effects of PEG-ADA were confirmed in vitro in a human full-thickness skin model. RESULTS: PEG-ADA effectively inhibited myofibroblast differentiation and reduced pulmonary fibrosis by 34.3% (with decreased collagen expression) (P = 0.0079; n = 6), dermal fibrosis by 51.8% (P = 0.0006; n = 6), and intestinal fibrosis by 17.7% (P = 0.0228; n = 6) in Fra-2 mice. Antifibrotic effects of PEG-ADA were also demonstrated in sclerodermatous chronic GVHD (reduced by 38.4%) (P = 0.0063; n = 8), and in a human full-thickness skin model. PEG-ADA treatment decreased inflammation and corrected the M2/Th2/group 2 innate lymphoid cell 2 bias. Moreover, PEG-ADA inhibited proliferation of pulmonary vascular smooth muscle cells (reduced by 40.5%) (P < 0.0001; n = 6), and prevented thickening of the vessel walls (reduced by 39.6%) (P = 0.0028; n = 6) and occlusions of pulmonary arteries (reduced by 63.9%) (P = 0.0147; n = 6). Treatment with PEG-ADA inhibited apoptosis of microvascular endothelial cells (reduced by 65.4%) (P = 0.0001; n = 6) and blunted the capillary rarefication (reduced by 32.5%) (P = 0.0199; n = 6). RNA sequencing demonstrated that treatment with PEG-ADA normalized multiple pathways related to fibrosis, vasculopathy, and inflammation in Fra-2 mice. CONCLUSION: Treatment with PEG-ADA ameliorates the 3 cardinal features of SSc in pharmacologically relevant and well-tolerated doses. These findings may have direct translational implications, as PEG-ADA has already been approved by the Food and Drug Administration for the treatment of patients with ADA-deficient severe combined immunodeficiency disease.
引用
- Zhang Y, Zhu H, Layritz F, et al. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. Arthritis Rheumatol. 2020. PMID: 32182396. doi:10.1002/art.41259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。